Statins and myocardial infarction: Type, dose, and administration time: Does it matter?
Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary a...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Papageorgiou, Nikolaos [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis - Kawamura, Takuji ELSEVIER, 2015, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:26 ; year:2016 ; number:5 ; pages:433-441 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.tcm.2016.01.001 |
|---|
| Katalog-ID: |
ELV024736228 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV024736228 | ||
| 003 | DE-627 | ||
| 005 | 20230625143351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tcm.2016.01.001 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016018000025.pica |
| 035 | |a (DE-627)ELV024736228 | ||
| 035 | |a (ELSEVIER)S1050-1738(16)00013-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 600 |a 670 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 100 | 1 | |a Papageorgiou, Nikolaos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Statins and myocardial infarction: Type, dose, and administration time: Does it matter? |
| 264 | 1 | |c 2016transfer abstract | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. | ||
| 520 | |a Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. | ||
| 650 | 7 | |a Cardiovascular outcomes |2 Elsevier | |
| 650 | 7 | |a STEMI |2 Elsevier | |
| 650 | 7 | |a Statins |2 Elsevier | |
| 700 | 1 | |a Zacharia, Effimia |4 oth | |
| 700 | 1 | |a Briasoulis, Alexandros |4 oth | |
| 700 | 1 | |a Androulakis, Emmanuel |4 oth | |
| 700 | 1 | |a Tousoulis, Dimitris |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Kawamura, Takuji ELSEVIER |t Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis |d 2015 |g Amsterdam [u.a.] |w (DE-627)ELV013458159 |
| 773 | 1 | 8 | |g volume:26 |g year:2016 |g number:5 |g pages:433-441 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.tcm.2016.01.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_62 | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 26 |j 2016 |e 5 |h 433-441 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
n p np |
|---|---|
| matchkey_str |
papageorgiounikolaoszachariaeffimiabrias:2016----:ttnadycrilnacinyeoenamnsr |
| hierarchy_sort_str |
2016transfer abstract |
| bklnumber |
51.00 |
| publishDate |
2016 |
| allfields |
10.1016/j.tcm.2016.01.001 doi GBVA2016018000025.pica (DE-627)ELV024736228 (ELSEVIER)S1050-1738(16)00013-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 670 VZ 51.00 bkl Papageorgiou, Nikolaos verfasserin aut Statins and myocardial infarction: Type, dose, and administration time: Does it matter? 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Cardiovascular outcomes Elsevier STEMI Elsevier Statins Elsevier Zacharia, Effimia oth Briasoulis, Alexandros oth Androulakis, Emmanuel oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Kawamura, Takuji ELSEVIER Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis 2015 Amsterdam [u.a.] (DE-627)ELV013458159 volume:26 year:2016 number:5 pages:433-441 extent:9 https://doi.org/10.1016/j.tcm.2016.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 GBV_ILN_62 51.00 Werkstoffkunde: Allgemeines VZ AR 26 2016 5 433-441 9 045F 610 |
| spelling |
10.1016/j.tcm.2016.01.001 doi GBVA2016018000025.pica (DE-627)ELV024736228 (ELSEVIER)S1050-1738(16)00013-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 670 VZ 51.00 bkl Papageorgiou, Nikolaos verfasserin aut Statins and myocardial infarction: Type, dose, and administration time: Does it matter? 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Cardiovascular outcomes Elsevier STEMI Elsevier Statins Elsevier Zacharia, Effimia oth Briasoulis, Alexandros oth Androulakis, Emmanuel oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Kawamura, Takuji ELSEVIER Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis 2015 Amsterdam [u.a.] (DE-627)ELV013458159 volume:26 year:2016 number:5 pages:433-441 extent:9 https://doi.org/10.1016/j.tcm.2016.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 GBV_ILN_62 51.00 Werkstoffkunde: Allgemeines VZ AR 26 2016 5 433-441 9 045F 610 |
| allfields_unstemmed |
10.1016/j.tcm.2016.01.001 doi GBVA2016018000025.pica (DE-627)ELV024736228 (ELSEVIER)S1050-1738(16)00013-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 670 VZ 51.00 bkl Papageorgiou, Nikolaos verfasserin aut Statins and myocardial infarction: Type, dose, and administration time: Does it matter? 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Cardiovascular outcomes Elsevier STEMI Elsevier Statins Elsevier Zacharia, Effimia oth Briasoulis, Alexandros oth Androulakis, Emmanuel oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Kawamura, Takuji ELSEVIER Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis 2015 Amsterdam [u.a.] (DE-627)ELV013458159 volume:26 year:2016 number:5 pages:433-441 extent:9 https://doi.org/10.1016/j.tcm.2016.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 GBV_ILN_62 51.00 Werkstoffkunde: Allgemeines VZ AR 26 2016 5 433-441 9 045F 610 |
| allfieldsGer |
10.1016/j.tcm.2016.01.001 doi GBVA2016018000025.pica (DE-627)ELV024736228 (ELSEVIER)S1050-1738(16)00013-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 670 VZ 51.00 bkl Papageorgiou, Nikolaos verfasserin aut Statins and myocardial infarction: Type, dose, and administration time: Does it matter? 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Cardiovascular outcomes Elsevier STEMI Elsevier Statins Elsevier Zacharia, Effimia oth Briasoulis, Alexandros oth Androulakis, Emmanuel oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Kawamura, Takuji ELSEVIER Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis 2015 Amsterdam [u.a.] (DE-627)ELV013458159 volume:26 year:2016 number:5 pages:433-441 extent:9 https://doi.org/10.1016/j.tcm.2016.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 GBV_ILN_62 51.00 Werkstoffkunde: Allgemeines VZ AR 26 2016 5 433-441 9 045F 610 |
| allfieldsSound |
10.1016/j.tcm.2016.01.001 doi GBVA2016018000025.pica (DE-627)ELV024736228 (ELSEVIER)S1050-1738(16)00013-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 670 VZ 51.00 bkl Papageorgiou, Nikolaos verfasserin aut Statins and myocardial infarction: Type, dose, and administration time: Does it matter? 2016transfer abstract 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. Cardiovascular outcomes Elsevier STEMI Elsevier Statins Elsevier Zacharia, Effimia oth Briasoulis, Alexandros oth Androulakis, Emmanuel oth Tousoulis, Dimitris oth Enthalten in Elsevier Science Kawamura, Takuji ELSEVIER Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis 2015 Amsterdam [u.a.] (DE-627)ELV013458159 volume:26 year:2016 number:5 pages:433-441 extent:9 https://doi.org/10.1016/j.tcm.2016.01.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 GBV_ILN_62 51.00 Werkstoffkunde: Allgemeines VZ AR 26 2016 5 433-441 9 045F 610 |
| language |
English |
| source |
Enthalten in Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis Amsterdam [u.a.] volume:26 year:2016 number:5 pages:433-441 extent:9 |
| sourceStr |
Enthalten in Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis Amsterdam [u.a.] volume:26 year:2016 number:5 pages:433-441 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Cardiovascular outcomes STEMI Statins |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis |
| authorswithroles_txt_mv |
Papageorgiou, Nikolaos @@aut@@ Zacharia, Effimia @@oth@@ Briasoulis, Alexandros @@oth@@ Androulakis, Emmanuel @@oth@@ Tousoulis, Dimitris @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013458159 |
| dewey-sort |
3610 |
| id |
ELV024736228 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV024736228</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625143351.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tcm.2016.01.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV024736228</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1050-1738(16)00013-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Papageorgiou, Nikolaos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Statins and myocardial infarction: Type, dose, and administration time: Does it matter?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cardiovascular outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">STEMI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Statins</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zacharia, Effimia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Briasoulis, Alexandros</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Androulakis, Emmanuel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tousoulis, Dimitris</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Kawamura, Takuji ELSEVIER</subfield><subfield code="t">Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis</subfield><subfield code="d">2015</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013458159</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:433-441</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tcm.2016.01.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2016</subfield><subfield code="e">5</subfield><subfield code="h">433-441</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Papageorgiou, Nikolaos |
| spellingShingle |
Papageorgiou, Nikolaos ddc 610 ddc 600 bkl 51.00 Elsevier Cardiovascular outcomes Elsevier STEMI Elsevier Statins Statins and myocardial infarction: Type, dose, and administration time: Does it matter? |
| authorStr |
Papageorgiou, Nikolaos |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013458159 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 600 - Technology 670 - Manufacturing |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 600 670 VZ 51.00 bkl Statins and myocardial infarction: Type, dose, and administration time: Does it matter? Cardiovascular outcomes Elsevier STEMI Elsevier Statins Elsevier |
| topic |
ddc 610 ddc 600 bkl 51.00 Elsevier Cardiovascular outcomes Elsevier STEMI Elsevier Statins |
| topic_unstemmed |
ddc 610 ddc 600 bkl 51.00 Elsevier Cardiovascular outcomes Elsevier STEMI Elsevier Statins |
| topic_browse |
ddc 610 ddc 600 bkl 51.00 Elsevier Cardiovascular outcomes Elsevier STEMI Elsevier Statins |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e z ez a b ab e a ea d t dt |
| hierarchy_parent_title |
Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis |
| hierarchy_parent_id |
ELV013458159 |
| dewey-tens |
610 - Medicine & health 600 - Technology 670 - Manufacturing |
| hierarchy_top_title |
Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013458159 |
| title |
Statins and myocardial infarction: Type, dose, and administration time: Does it matter? |
| ctrlnum |
(DE-627)ELV024736228 (ELSEVIER)S1050-1738(16)00013-X |
| title_full |
Statins and myocardial infarction: Type, dose, and administration time: Does it matter? |
| author_sort |
Papageorgiou, Nikolaos |
| journal |
Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis |
| journalStr |
Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
433 |
| author_browse |
Papageorgiou, Nikolaos |
| container_volume |
26 |
| physical |
9 |
| class |
610 610 DE-600 610 VZ 600 670 VZ 51.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Papageorgiou, Nikolaos |
| doi_str_mv |
10.1016/j.tcm.2016.01.001 |
| dewey-full |
610 600 670 |
| title_sort |
statins and myocardial infarction: type, dose, and administration time: does it matter? |
| title_auth |
Statins and myocardial infarction: Type, dose, and administration time: Does it matter? |
| abstract |
Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. |
| abstractGer |
Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. |
| abstract_unstemmed |
Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 GBV_ILN_62 |
| container_issue |
5 |
| title_short |
Statins and myocardial infarction: Type, dose, and administration time: Does it matter? |
| url |
https://doi.org/10.1016/j.tcm.2016.01.001 |
| remote_bool |
true |
| author2 |
Zacharia, Effimia Briasoulis, Alexandros Androulakis, Emmanuel Tousoulis, Dimitris |
| author2Str |
Zacharia, Effimia Briasoulis, Alexandros Androulakis, Emmanuel Tousoulis, Dimitris |
| ppnlink |
ELV013458159 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.tcm.2016.01.001 |
| up_date |
2024-07-06T22:12:22.593Z |
| _version_ |
1803869426909446144 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV024736228</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625143351.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.tcm.2016.01.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV024736228</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1050-1738(16)00013-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Papageorgiou, Nikolaos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Statins and myocardial infarction: Type, dose, and administration time: Does it matter?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with ST-elevation myocardial infarction (STEMI) constitute a vulnerable group that demands the careful assessment and application of all the up-to-date clinical and experimental knowledge, with final aim, the improvement of their prognosis. Statins are an indispensable part of the primary and secondary prevention of coronary artery disease (CAD), not only due to their strong hypolipidemic effect, but also due to their numerous pleiotropic properties that play an important role in the treatment of CAD, especially when the more vulnerable group of STEMI patients is addressed. Nevertheless, there are still issues that require further discussion and clarification, such as the type of statin, the dose of the regimen, the administration time, and the treatment duration.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cardiovascular outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">STEMI</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Statins</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zacharia, Effimia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Briasoulis, Alexandros</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Androulakis, Emmanuel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tousoulis, Dimitris</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Kawamura, Takuji ELSEVIER</subfield><subfield code="t">Sa1638 Colonoscopy Withdrawal Time and Adenoma Detection Rate: a Japanese Multicenter Analysis</subfield><subfield code="d">2015</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013458159</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:26</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:5</subfield><subfield code="g">pages:433-441</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.tcm.2016.01.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">26</subfield><subfield code="j">2016</subfield><subfield code="e">5</subfield><subfield code="h">433-441</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400917 |